RUO labelling: what a research vial must state, and what its file must hold

A correct research vial label answers five questions without anyone opening a file: what the substance is, which batch it came from, how much the vial nominally holds, under what conditions it is stored, and what it is intended for. The file that travels with it covers the rest: a certificate of analysis for that specific batch, a safety data sheet in the form Annex II of REACH imposes, and a receiving record that ties the physical vial to the other two. When even one of those is missing, the material does not stop existing — it stops being documented, and in a laboratory undocumented means unusable for anything that will later have to be reproduced or defended.

The text printed on the vial matters as much as the contents, and not metaphorically. Under EU law a substance can become a medicinal product simply because it is presented as one: Directive 2001/83/EC defines a medicinal product as "any substance or combination of substances presented as having properties for treating or preventing disease in human beings" — a definition triggered by the presentation itself, independently of any pharmacological action ^[1]. Labelling is therefore not a question of tidiness; it is a question of classification.

What "Research Use Only" actually means in law

RUO is not a licence, an approval, or a certification category. It is a statement of intended use — and precisely because it is a statement, it holds only for as long as everything else said about the material does not contradict it. Regulation (EU) 2017/746 on in vitro diagnostic medical devices explicitly delimits its own scope so that it is separated from general laboratory products and from products intended solely for research, provided the manufacturer assigns them no medical purpose ^[2]. That proviso is the whole case: a single implied medical purpose moves the material into a regulatory regime with entirely different obligations.

The US FDA states the same logic even more bluntly. In its 2013 final guidance on the distribution of products labelled RUO or IUO, the agency says the label itself is not determinative: it weighs the total circumstances — promotional material, technical support, knowledge of how customers actually use the product — to judge whether the stated intended use is the real one ^[5]. A label does not work as a shield over text that says something else. It is the summary of a consistency that must exist across everything surrounding the product, or it does not exist at all.

The fields that belong on a vial label

There is no single European standard for an "RUO label". There are, however, three sources that together define a de facto minimum. CLP requires, for any substance classified as hazardous, the supplier's name, address and telephone number, the product identifiers, the hazard pictograms, the signal word and the hazard and precautionary statements ^[3]. ICH Q7 adds the batch-traceability logic: for materials with an expiry date, that date belongs on both the label and the certificate of analysis; for materials with a retest date, the retest date belongs on the label and/or the certificate ^[6]. ISO/IEC 17025 supplies the third requirement from the receiving side: unambiguous identification of every item, maintained for as long as it remains in the laboratory ^[7].

On very small packaging the above does not physically fit, and CLP provides derogations for exactly that case ^[3]. The practical answer is two-tier labelling: the vial carries substance identity, quantity, batch number and the use statement, while the outer packaging carries the full hazard label. What is not an answer is a marker pen on the cap. A handwritten symbol on a closure is not labelling — it is a note that will rub off, and the closure does not permanently travel with the same vial in any case.

The batch number: the field that holds the others together

The batch number is the only field on the label that nothing else can replace. The substance name can be confirmed analytically, the quantity can be weighed, the purity can be measured again; a lost batch identity cannot be recovered by any measurement. ICH Q7 treats the certificate of analysis as a batch document in exactly this sense: an authentic certificate is issued per batch on request, carries the material name with its grade where relevant, the batch number and the release date, and documents the original manufacturer so that traceability survives the full length of the supply chain ^[6].

• The batch number is copied into the receiving log on the day of receipt, not on the day it is eventually needed.
• No vial is ever relabelled with a label that covers the original; a new label goes beside it, never over it.
• If contents are transferred to another container, the new container carries an internal code that refers explicitly to the original batch — unambiguous identification has to survive the transfer ^[7].
• Two batches of the same substance are never merged or stored in a single container, however closely their certificates agree.
• The certificate of analysis is filed with the batch number inside the filename; if it takes a search to find, one day it will not be found.

Storage conditions: what the terms actually mean

"Store in a cool place" is not a storage condition; it is a wish. The terms that appear on labels and certificates have numeric definitions, and General Chapter 659 of the United States Pharmacopeia gives the most widely used set ^[8]. We reproduce them because this is the vocabulary you will meet in supplier documents — not because a research material is subject to a pharmacopoeia, which it is not.

Two things the label rarely states and the file must. First, whether the stated condition applies to the sealed lyophilised material or to the reconstituted solution — the two values almost never coincide, and confusing them is among the commonest handling errors. Second, how many freeze–thaw excursions the material is expected to tolerate before it falls outside specification. If the supplier does not state it, the correct entry in the record is not "unlimited" but "not stated", and the freezer log records every opening so the question can be answered after the fact.

The batch file: certificate of analysis, safety data sheet, receiving record

The certificate of analysis is the principal document in the file, and ICH Q7 defines what complete means: it lists every test performed against pharmacopoeial or in-house specifications, with the acceptance limits and the numerical results, rather than a blanket statement of conformity ^[6]. A one-page "certificate" reading "passes specification" without naming the specification, the method or the result is not an incomplete document — it is a different kind of document altogether.

• Material name and batch number, identical to the vial label.
• Identity as well as purity: mass spectrometry or an equivalent method showing the substance is what the label claims — remembering that a mass match confirms the mass, not the sequence.
• Purity with the method and analytical conditions named — an HPLC figure without the chromatogram is an assertion, not a result.
• Water content, acetate content or residual solvents wherever the synthesis route makes them expected.
• Issue date, expiry or retest date, and the identity of the laboratory that performed the testing ^[6].

The safety data sheet is the second mandatory document and, unlike the certificate, its form is completely fixed: sixteen sections in a prescribed order, under Annex II of REACH as amended by Regulation (EU) 2020/878 — a format mandatory for every safety data sheet circulating in the EU since 1 January 2023 ^[4]. A sheet with twelve sections, or with sections out of order, is not an "older version"; it is a non-compliant document, and it is one of the fastest signals that a supplier reproduces paperwork rather than producing it.

We owe the reader honesty about the limits of all of this, because the market rarely offers any. A certificate of analysis is a third-party assertion, not proof: it confirms what someone measured in some sample, not what is in the particular vial in your hand. There is no accredited certification scheme covering "research peptides" as a category, and the published testing of material sold outside a regulated supply chain is limited, methodologically heterogeneous and hard to generalise from. What makes a certificate checkable is not the logo at the top of it but the batch match: the same code on the label, the certificate and the shipping document. Where that chain breaks, the document adds no information.

What an RUO label must never say

The hard part of RUO labelling is not what goes on, but what stays off. Because the European concept of a medicinal product by presentation is triggered by the characterisation rather than the composition ^[1], and because enforcement examines the total circumstances rather than the wording of the statement alone ^[5], the label has to be entirely silent on anything concerning use in an organism.

• No therapeutic, preventive or diagnostic reference, not even by implication or by naming a condition.
• No administration instruction, route or regimen, in any form.
• No claim of suitability for clinical or diagnostic use — this is precisely the boundary the FDA examines when judging whether an RUO statement reflects reality ^[5].
• No "pharmaceutical grade" marking without a corresponding monograph and full testing against it; the phrase only means something as a reference to a named standard.
• No comparison to an approved medicinal product, not even as a statement of equivalence.

The Greek framework: EOF, ESYD, ELOT

In Greece one requirement is missed almost systematically on imported material: CLP provides that the label is written in the official language of the Member State in whose market the substance is placed, unless that Member State provides otherwise ^[3]. An English-only hazard label on material placed on the Greek market does not satisfy that requirement. The practical answer is a bilingual label or a Greek-language insert that stays permanently with the packaging — and, in every case, a Greek-language safety data sheet.

As for the bodies, the division of responsibility is simpler than it looks. EOF, the National Organisation for Medicines, is the competent authority for human medicinal products in Greece, and therefore the body that will concern itself with a material only if its labelling or presentation pulls it into the medicinal field — exactly the outcome the research-use statement exists to prevent ^[1]. Laboratory accreditation is granted by ESYD, the national accreditation system, against ELOT EN ISO/IEC 17025, the Greek adoption of the international standard ^[7]. If you are commissioning analysis from a Greek laboratory, the useful question is not whether it is "certified" — a word that means nothing here — but whether the specific method falls inside its published scope of accreditation.

A receiving checklist

1. Photograph the sealed parcel before opening it, with the shipping marks and the condition of the packaging visible.
2. Match the name and batch number across vial, delivery note and certificate of analysis; a difference of even one character is recorded as a deviation to investigate, not as a typo.
3. Check the integrity of the closure and seal, and the appearance of the contents against the description on the certificate.
4. Record the arrival temperature where the material ships chilled — or note explicitly that it was not measured, which is also information.
5. File the certificate of analysis and the safety data sheet with the batch number in each filename.
6. Enter the vial in the inventory register with its storage location, receipt date and expiry or retest date.
7. Confirm the intended-use statement is present and legible; its absence is recorded as a supplier finding.